Skip to main content
Erschienen in: Hepatology International 3/2009

01.09.2009 | Case Report

Diffuse intrahepatic recurrence after percutaneous radiofrequency ablation for solitary and small hepatocellular carcinoma

verfasst von: Yoshiyuki Mori, Hideyuki Tamai, Naoki Shingaki, Kosaku Moribata, Tatsuya Shiraki, Hisanobu Deguchi, Kazuki Ueda, Shotaro Enomoto, Hiroto Magari, Izumi Inoue, Takao Maekita, Mikitaka Iguchi, Kimihiko Yanaoka, Masashi Oka, Masao Ichinose

Erschienen in: Hepatology International | Ausgabe 3/2009

Einloggen, um Zugang zu erhalten

Abstract

Two patients developed segmental, diffuse intrahepatic recurrence after percutaneous radiofrequency ablation (RFA) to treat a primary, solitary, and small (2.5 cm) hepatocellular carcinoma (HCC). Despite the size of the HCC, levels of the tumor markers (α-fetoprotein, α-fetoprotein-L3%, and des-γ-carboxyprothrombin) were all elevated before RFA, and tumors in both patients were contiguous with a major branch of the portal vein. Tumor biopsies of both patients revealed moderately differentiated HCC but diagnostic imaging showed an area of reduced tumor blood flow, suggesting a poorly differentiated component. Since early detection of post-RFA malignancies by standard ultrasonography and contrast-enhanced computed tomography was difficult, the most sensitive indicator of recurrence in these two patients was the elevated tumor markers. The diffuse intrahepatic recurrence was thought to be caused by increased intratumoral pressure during RFA, resulting in the dissemination of cancer cells through the contiguous portal vein. The clinical course of these tumors indicate that the choice of RFA should be carefully considered when treating specific subtype of HCC that is adjacent to main portal vein branch and involves a possible poorly differentiated component and that surgical resection or combinations of RFA with other treatment modalities such as transcatheter arterial chemoembolization should be considered as alternative treatment strategies.
Literatur
1.
Zurück zum Zitat Rossi S, Di Stasi M, Buscarini E, Quaretti P, Garbagnati F, Squassante L, et al. Percutaneous RF interstitial ablation in the treatment of hepatic cancer. AJR Am J Roentgenol 1996;167:759–768PubMed Rossi S, Di Stasi M, Buscarini E, Quaretti P, Garbagnati F, Squassante L, et al. Percutaneous RF interstitial ablation in the treatment of hepatic cancer. AJR Am J Roentgenol 1996;167:759–768PubMed
3.
Zurück zum Zitat Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005;103:1201–1209. doi:10.1002/cncr.20892 PubMedCrossRef Tateishi R, Shiina S, Teratani T, Obi S, Sato S, Koike Y, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer 2005;103:1201–1209. doi:10.​1002/​cncr.​20892 PubMedCrossRef
4.
Zurück zum Zitat Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nation-wide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000;32:1224–1229. doi:10.1053/jhep.2000.20456 PubMedCrossRef Arii S, Yamaoka Y, Futagawa S, Inoue K, Kobayashi K, Kojiro M, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nation-wide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000;32:1224–1229. doi:10.​1053/​jhep.​2000.​20456 PubMedCrossRef
5.
Zurück zum Zitat Llovet JM, Vilana R, Brú C, Bianchi L, Salmeron JM, Boix L, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001;33:1124–1129. doi:10.1053/jhep.2001.24233 PubMedCrossRef Llovet JM, Vilana R, Brú C, Bianchi L, Salmeron JM, Boix L, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 2001;33:1124–1129. doi:10.​1053/​jhep.​2001.​24233 PubMedCrossRef
6.
7.
Zurück zum Zitat Seki T, Tamai T, Ikeda K, Imamura M, Nishimura A, Yamashiki N, et al. Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumour region. Eur J Gastroenterol Hepatol 2001;13:291–294. doi:10.1097/00042737-200103000-00014 PubMedCrossRef Seki T, Tamai T, Ikeda K, Imamura M, Nishimura A, Yamashiki N, et al. Rapid progression of hepatocellular carcinoma after transcatheter arterial chemoembolization and percutaneous radiofrequency ablation in the primary tumour region. Eur J Gastroenterol Hepatol 2001;13:291–294. doi:10.​1097/​00042737-200103000-00014 PubMedCrossRef
8.
Zurück zum Zitat Portolani N, Tiberio GA, Ronconi M, Coniglio A, Ghidoni S, Gaverini G, et al. Aggressive recurrence after radiofrequency ablation of liver neoplasms. Hepatogastroenterology 2003;50:2179–2184PubMed Portolani N, Tiberio GA, Ronconi M, Coniglio A, Ghidoni S, Gaverini G, et al. Aggressive recurrence after radiofrequency ablation of liver neoplasms. Hepatogastroenterology 2003;50:2179–2184PubMed
10.
Zurück zum Zitat Ruzzenente A, Manzoni GD, Molfetta M, Pachera S, Genco B, Donataccio M, et al. Rapid progression of hepatocellular carcinoma after radiofrequency ablation. World J Gastroenterol 2004;10:1137–1140PubMed Ruzzenente A, Manzoni GD, Molfetta M, Pachera S, Genco B, Donataccio M, et al. Rapid progression of hepatocellular carcinoma after radiofrequency ablation. World J Gastroenterol 2004;10:1137–1140PubMed
11.
Zurück zum Zitat Tamaki K, Shimizu I, Oshio A, Fukuno H, Inoue H, Tsutsui A, et al. Influence of large intrahepatic blood vessels on the gross and histological characteristics of lesions produced by radiofrequency ablation in a pig liver model. Liver Int 2004;24:696–701. doi:10.1111/j.1478-3231.2004.0952.x PubMedCrossRef Tamaki K, Shimizu I, Oshio A, Fukuno H, Inoue H, Tsutsui A, et al. Influence of large intrahepatic blood vessels on the gross and histological characteristics of lesions produced by radiofrequency ablation in a pig liver model. Liver Int 2004;24:696–701. doi:10.​1111/​j.​1478-3231.​2004.​0952.​x PubMedCrossRef
12.
Zurück zum Zitat Honda H, Tajima T, Kajiyama K, Kuroiwa T, Yoshimitsu K, Irie H, et al. Vascular changes in hepatocellular carcinoma: correlation of radiologic and pathologic findings. AJR Am J Roentgenol 1999;173:1213–1217PubMed Honda H, Tajima T, Kajiyama K, Kuroiwa T, Yoshimitsu K, Irie H, et al. Vascular changes in hepatocellular carcinoma: correlation of radiologic and pathologic findings. AJR Am J Roentgenol 1999;173:1213–1217PubMed
13.
Zurück zum Zitat Asayama Y, Yoshimitsu K, Irie H, Nishihara Y, Aishima S, Tajima T, et al. Poorly versus moderately differentiated hepatocellular carcinoma: vascularity assessment by computed tomographic hepatic angiography in correlation with histologically counted number of unpaired arteries. J Comput Assist Tomogr 2007;31:188–192. doi:10.1097/01.rct.0000236417.82395.57 PubMedCrossRef Asayama Y, Yoshimitsu K, Irie H, Nishihara Y, Aishima S, Tajima T, et al. Poorly versus moderately differentiated hepatocellular carcinoma: vascularity assessment by computed tomographic hepatic angiography in correlation with histologically counted number of unpaired arteries. J Comput Assist Tomogr 2007;31:188–192. doi:10.​1097/​01.​rct.​0000236417.​82395.​57 PubMedCrossRef
14.
15.
Zurück zum Zitat Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alphafetoprotein and des-gamma-carboxyprothrombin in histologically proven hepatocellular carcinoma in United States. Dig Dis Sci 2007;52:776–782. doi:10.1007/s10620-006-9541-2 PubMedCrossRef Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alphafetoprotein and des-gamma-carboxyprothrombin in histologically proven hepatocellular carcinoma in United States. Dig Dis Sci 2007;52:776–782. doi:10.​1007/​s10620-006-9541-2 PubMedCrossRef
16.
Zurück zum Zitat Yoshida S, Kurokohchi K, Arima K, Masaki T, Hosomi N, Funaki T, et al. Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol 2002;20:305–309PubMed Yoshida S, Kurokohchi K, Arima K, Masaki T, Hosomi N, Funaki T, et al. Clinical significance of lens culinaris agglutinin-reactive fraction of serum alpha-fetoprotein in patients with hepatocellular carcinoma. Int J Oncol 2002;20:305–309PubMed
17.
Zurück zum Zitat Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto M, et al. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol 2002;17:772–778. doi:10.1046/j.1440-1746.2002.02806.x PubMedCrossRef Okuda H, Nakanishi T, Takatsu K, Saito A, Hayashi N, Yamamoto M, et al. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol 2002;17:772–778. doi:10.​1046/​j.​1440-1746.​2002.​02806.​x PubMedCrossRef
19.
Zurück zum Zitat Kashiwagi K, Furusyo N, Kubo N, Nakashima H, Nomura H, Kashiwagi S, et al. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development. J Infect Chemother 2003;9:333–340. doi:10.1007/s10156-003-0271-5 PubMedCrossRef Kashiwagi K, Furusyo N, Kubo N, Nakashima H, Nomura H, Kashiwagi S, et al. A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development. J Infect Chemother 2003;9:333–340. doi:10.​1007/​s10156-003-0271-5 PubMedCrossRef
21.
Zurück zum Zitat Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051–1055. doi:10.1016/S0140-6736(95)91739-X PubMedCrossRef Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:1051–1055. doi:10.​1016/​S0140-6736(95)91739-X PubMedCrossRef
22.
Zurück zum Zitat Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001;134:963–967PubMed Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, et al. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001;134:963–967PubMed
23.
Zurück zum Zitat Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228–232PubMedCrossRef Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, et al. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor—a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228–232PubMedCrossRef
24.
Zurück zum Zitat Saborido BP, Díaz JC, de Los Galanes SJ, Segurola CL, de Usera MA, Garrido MD, et al. Does preoperative fine needle aspiration-biopsy produce tumor recurrence in patients following liver transplantation for hepatocellular carcinoma? Transplant Proc 2005;37:3874–3877. doi:10.1016/j.transproceed.2005.09.169 PubMedCrossRef Saborido BP, Díaz JC, de Los Galanes SJ, Segurola CL, de Usera MA, Garrido MD, et al. Does preoperative fine needle aspiration-biopsy produce tumor recurrence in patients following liver transplantation for hepatocellular carcinoma? Transplant Proc 2005;37:3874–3877. doi:10.​1016/​j.​transproceed.​2005.​09.​169 PubMedCrossRef
25.
Zurück zum Zitat Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 2007;33:437–447. doi:10.1016/j.ctrv.2007.04.001 PubMedCrossRef Stigliano R, Marelli L, Yu D, Davies N, Patch D, Burroughs AK. Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev 2007;33:437–447. doi:10.​1016/​j.​ctrv.​2007.​04.​001 PubMedCrossRef
26.
Zurück zum Zitat Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007;13:423–433. doi:10.1158/1078-0432.CCR-06-1357 CrossRef Seo S, Hatano E, Higashi T, Hara T, Tada M, Tamaki N, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography predicts tumor differentiation, P-glycoprotein expression, and outcome after resection in hepatocellular carcinoma. Clin Cancer Res 2007;13:423–433. doi:10.​1158/​1078-0432.​CCR-06-1357 CrossRef
27.
Zurück zum Zitat Imai Y, Murakami T, Yoshida S, Nishikawa M, Ohsawa M, Tokunaga K, et al. Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology 2000;32:205–212. doi:10.1053/jhep.2000.9113 PubMedCrossRef Imai Y, Murakami T, Yoshida S, Nishikawa M, Ohsawa M, Tokunaga K, et al. Superparamagnetic iron oxide-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading. Hepatology 2000;32:205–212. doi:10.​1053/​jhep.​2000.​9113 PubMedCrossRef
28.
Zurück zum Zitat Asahina Y, Izumi N, Uchihara M, Noguchi O, Ueda K, Inoue K, et al. Assessment of Kupffer cells by ferumoxides-enhanced MR imaging is beneficial for diagnosis of hepatocellular carcinoma: comparison of pathological diagnosis and perfusion patterns assessed by CT hepatic arteriography and CT arterioportography. Hepatol Res 2003;27:196–204. doi:10.1016/S1386-6346(03)00261-4 PubMedCrossRef Asahina Y, Izumi N, Uchihara M, Noguchi O, Ueda K, Inoue K, et al. Assessment of Kupffer cells by ferumoxides-enhanced MR imaging is beneficial for diagnosis of hepatocellular carcinoma: comparison of pathological diagnosis and perfusion patterns assessed by CT hepatic arteriography and CT arterioportography. Hepatol Res 2003;27:196–204. doi:10.​1016/​S1386-6346(03)00261-4 PubMedCrossRef
29.
Zurück zum Zitat Huppertz A, Haraida S, Kraus A, Zech CJ, Scheidler J, Breuer J, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT—initial observations. Radiology 2005;234:468–478. doi:10.1148/radiol.2342040278 PubMedCrossRef Huppertz A, Haraida S, Kraus A, Zech CJ, Scheidler J, Breuer J, et al. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT—initial observations. Radiology 2005;234:468–478. doi:10.​1148/​radiol.​2342040278 PubMedCrossRef
30.
Zurück zum Zitat Halavaara J, Breuer J, Ayuso C, Balzer T, Bellin MF, Blomqvist L, et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT—a multicenter trial. J Comput Assist Tomogr 2006;30:345–354. doi:10.1097/00004728-200605000-00001 PubMedCrossRef Halavaara J, Breuer J, Ayuso C, Balzer T, Bellin MF, Blomqvist L, et al. Liver tumor characterization: comparison between liver-specific gadoxetic acid disodium-enhanced MRI and biphasic CT—a multicenter trial. J Comput Assist Tomogr 2006;30:345–354. doi:10.​1097/​00004728-200605000-00001 PubMedCrossRef
31.
Zurück zum Zitat Sheen IS, Jeng KS, Shih SC, Wang PC, Chang WH, Wang HY, et al. Does surgical resection of hepatocellular carcinoma accelerate cancer dissemination? World J Gastroenterol 2004;10:31–36PubMed Sheen IS, Jeng KS, Shih SC, Wang PC, Chang WH, Wang HY, et al. Does surgical resection of hepatocellular carcinoma accelerate cancer dissemination? World J Gastroenterol 2004;10:31–36PubMed
Metadaten
Titel
Diffuse intrahepatic recurrence after percutaneous radiofrequency ablation for solitary and small hepatocellular carcinoma
verfasst von
Yoshiyuki Mori
Hideyuki Tamai
Naoki Shingaki
Kosaku Moribata
Tatsuya Shiraki
Hisanobu Deguchi
Kazuki Ueda
Shotaro Enomoto
Hiroto Magari
Izumi Inoue
Takao Maekita
Mikitaka Iguchi
Kimihiko Yanaoka
Masashi Oka
Masao Ichinose
Publikationsdatum
01.09.2009
Verlag
Springer-Verlag
Erschienen in
Hepatology International / Ausgabe 3/2009
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-009-9131-4

Weitere Artikel der Ausgabe 3/2009

Hepatology International 3/2009 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Wie managen Sie die schmerzhafte diabetische Polyneuropathie?

10.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Mit Capsaicin-Pflastern steht eine neue innovative Therapie bei schmerzhafter diabetischer Polyneuropathie zur Verfügung. Bei therapierefraktären Schmerzen stellt die Hochfrequenz-Rückenmarkstimulation eine adäquate Option dar.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.